GuideNephrology

COVID-19 and the kidney: acute kidney injury and antiviral dosing

Summary of kidney involvement in SARS-CoV-2 infection (frequency, mechanisms, prognosis) and of the kidney-related considerations of current treatment.

Updated 3 November 2026

When to use it

In patients with COVID-19 who are hospitalised, have chronic kidney disease, are on dialysis or have a kidney transplant, to prevent, detect and manage kidney injury.

Warning

The original 2020 document is outdated. This sheet summarises the evidence and current CDC recommendations as of November 2026; antiviral labels change: check them before prescribing.

Frequency and prognosis

During the first wave in New York (5,449 hospitalised adults, 2020), 36.6% developed AKI and 14.3% of these needed dialysis. AKI was associated mainly with mechanical ventilation (89.7% of ventilated patients) and with poor prognosis. With current variants, vaccination and antivirals, severe COVID-19 and AKI are much less common.

Keep reading in the app

  • Mechanisms
  • Management
  • Antivirals and kidney function (current)

Practical tip

COVID-19-associated AKI is diagnosed and staged with standard KDIGO criteria and managed like other AKI: there is no kidney-specific treatment.

2 more practical tips in the app.

Reference

Official source: CDC: outpatient treatment of COVID-19

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top